Endometrial carcinomas are histologically classified as endometrioid, assumed to originate from hyperplastic endometrium, or non-endometrioid carcinomas, assumed to originate from atrophic endometrium. However, both on a histological and a molecular level there are indications that there are more carcinoma types and carcinogenetic pathways. This study aims to analyze endometrial carcinogenesis on a molecular level. The presence of known KRAS, PIK3CA, AKT1, CTNNB1, BRAF, EGFR and NRAS mutations was studied in proliferative, atrophic and hyperplastic endometrium, endometrioid and serous carcinomas, and the endometrium next to these carcinomas, using single molecule Molecular Inversion Probes. Mutations were found in 9 (15%) of the 62 non atypical, and in 6 (18%) of the 34 atypical hyperplasia cases. In comparison, mutations were found in 1 (3%) of the simple, and 8 (30%) of the 27 complex hyperplasia cases. In 12/22 (55%) endometrioid carcinomas, a mutation was found. The KRAS gene was most often mutated in carcinomas next to hyperplastic endometrium, whereas PIK3CA and CTNNB1 mutations were found in endometrioid carcinomas with adjacent atrophic endometrium. Complex hyperplasia rather than atypical hyperplasia appears to be the most important lesion in the carcinogenesis of endometrioid carcinomas, and KRAS, PIK3CA and CTNNB1 mutations appear to play an important role in this process. Carcinogenesis of endometrioid carcinomas next to hyperplasia seems to be different to that of those next to atrophia. The value of these findings in managing endometrial hyperplasia and carcinoma should be studied.
Introduction
Endometrial cancer is the most common gynecological malignancy in the developed world, and its incidence is rising (1) . Traditionally, endometrial carcinomas are divided into those with endometrioid and those with non-endometrioid histology, which were shown to have different molecular profiles as well. Endometrioid carcinomas are characterized by a heterogeneous molecular profile of mutations in PTEN, KRAS, CTNNB1 and PIK3CA, whereas TP53 mutations are most common in non-endometrioid carcinomas (2) (3) (4) .
Endometrioid and non-endometrioid carcinomas are assumed to follow different carcinogenetic pathways as well.
Normal postmenopausal endometrium is atrophic, but can become hyperplastic, mainly as a result of unopposed estrogen stimulation (5) . Endometrial hyperplasia can be categorized based on both the presence of simple or complex architecture, and the absence or presence of atypical nuclei (6) . It is assumed that endometrioid carcinomas originate mainly from hyperplasia with atypia, and the World Health Organisation (WHO) therefore advises to categorize hyperplasia as either non-atypical or atypical, and to perform a hysterectomy when atypia is present (7) (8) (9) . Non-endometrioid carcinomas on the other hand are assumed to originate from atrophic endometrium (10) . On a molecular level, PTEN and KRAS mutations are assumed to be early events in endometrioid carcinogenesis, already present in endometrial hyperplasia, whereas PIK3CA mutations appear related to invasive transformation (11) (12) (13) . In serous carcinomas, TP53 mutations were shown play an important role, but other non-endometrioid carcinomas have more heterogeneous molecular profiles (2, 3, 14) . Moreover, it has been suggested that some non-endometrioid carcinomas are in fact dedifferentiated endometrioid carcinomas, as they have both non-endometrioid and endometrioid molecular characteristics (2, 3) .
In a recent study analyzing the endometrium of asymptomatic postmenopausal women, who were expected to have atrophic endometrium, a high prevalence of endometrial hyperplasia, including hyperplasia with atypical nuclei was found (15) . In addition, although endometrioid carcinomas are assumed to originate in endometrial hyperplasia, the endometrium next to these carcinomas is atrophic in around 20% of the cases, and these cases were shown to have a worse prognosis (16) . Moreover, studies categorizing endometrial carcinomas based on their molecular profiles have concluded that there are most likely more than two subgroups (17, 18) .
These recent findings challenge the dualistic nature of endometrial carcinogenesis, and the fact that a large proportion of the atypical endometrial hyperplasia will progress into a carcinoma. It is therefore important to analyze the molecular characteristics of endometrial carcinogenesis in relation to these recent findings. This information is not only valuable for the clinical management of endometrial carcinomas, but for the management of endometrial hyperplasia as well.
Materials and methods

Cases
This study included a benign (proliferative and atrophic endometrium), a premalignant (hyperplastic endometrium) and a malignant (endometrioid carcinomas and serous carcinomas) cohort. The latter cohort also included the endometrium adjacent to the carcinomas. (16, 19) .
All slides from these three cohorts were centrally collected at the Radboud University Medical Center, a referral hospital for gynecological oncology.
They were reviewed using the criteria below by an expert gynecological pathologist (JB), who was unaware of the previous histological diagnosis and the clinical course. Atrophic endometrium was defined as shallow endometrium with a thin basal layer and with a few tubular glands lined by inactive endometrium (7) . Proliferative endometrium was defined as glandular proliferation, but no hyperplasia based on the gland:stroma ratio in postmenopausal women, and as widely spread, sometimes tortuous, tubular glands showing mitotic activity and abundant stroma in premenopausal women (7) . Hyperplasia was defined as glandular proliferation with an increased gland:stroma ratio of 3:1, and was classified as simple or complex according to the (old) World Health Organization criteria (6) . Atypia was defined as enlarged, rounded, polymorphic nuclei with loss of polarity, prominent nucleoli, chromatin clumping and an increased nucleus to cytoplasm ratio (6) . Endometrioid carcinomas were distinguished from endometrial hyperplasia based on the presence of stromal invasion, and only those with no more than 5% solid, non-squamous areas were considered to be grade 1 (20) . Carcinomas with papillae and pleiomorphic tumor cells with frequent mitoses and necrosis were considered to be of the serous type (20) .
Representative areas to be dissected for DNA isolation were marked, and both the carcinoma and adjacent tissue were marked in the carcinoma groups. Cases which did not belong to the respective cohorts after revision anymore, and those with no or insufficient tissue for review were excluded.
DNA isolation
The previously marked representative areas were separated by either macro-or laser microdissection from, respectively, 20 or 10 µm thick section from corresponding formalin-fixed, paraffin embedded tissue. For laser micro dissection, slides were mounted on poly ethylene napthalate (PEN) membrane slides (Leica Microsystems, Buffalo Grove, IL), pretreated with ultraviolet light, and visualized with hematoxylin.
The separated tissue was digested overnight at 56°C in TET-lysis buffer (10 mM Tris/HCL pH 8.5, 1 mM EDTA pH 8.0, 0.01% Tween-20) with 5% Chelex-100 (Bio-Rad, Hercules, CA) and 0.2% proteinase K. Subsequently, proteinase K was inactivated at 95°C for 10 min, and the supernatant was transferred after centrifugation into a clean tube. DNA concentration was determined using the Qubit Broad Range Kit (Thermo Fisher Scientific, Waltham, MA).
smMIP design and library preparation
The samples were analyzed using single molecule Molecular Inversion Probes (smMIPs). Both the design of the smMIPs and the preparation of the library were performed as previously described (21, 22) . In short, a panel of smMIPs, targeting both strands of hotspots listed in Supplementary Table 1, available at Carcinogenesis Online, in a tiled manner, was designed. The smMIP probes contained extension and ligation probe arms (together 40 bp long), and these arms were separated by an 112 bp gap. These genes were chosen because they have been previously described to play a role in the PI3K/AKT, MAP/ERK and Wnt pathways, which play a role in the development of endometrial carcinomas, and because mutations of all of these genes have been previously described in endometrial carcinomas (12, (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) . A common backbone sequence was inserted between the targeting arms and eight nucleotides were inserted between the backbone and ligation probe. The smMIP probes were produced by Integrated DNA Technologies (Leuven, Belgium) were mixed and phosphorylated with 1 ul of T4 polynucleotide kinase (M0201, New England Biolabs, Ipswich, MA) per 25 ul of 100 uM smMIPs and ATP-containing T4 DNA ligase buffer (B0202, New England Biolabs, Ipswich, MA). The molecular ratio between genomic DNA and smMIPs was set to 1:3200 for every individual smMIP, and genomic DNA input was expected to be 100 ng.
A capture mix was made by adding the phosphorylated smMIPpool, 1 unit of Ampligase DNA ligase (A0110K, Epibio, Madison, WA) with Ampligase Buffer (A1905B, Epibio, Madison, WA), 3.2 units of Hemo Klentaq (M0332, New England Biolabs, Ipswich, MA) and 8 µmol of dNTPs (28-4065-20/-12/-22/-32, GE Healthcare, Hoevelaken, the Netherlands) to 20 µl of sample containing genomic DNA. After denaturation at 95°C for 10 min, the mix was incubated for probe hybridization, extension and ligation at 60°C for 18 h and cooled prior to exonuclease treatment. Exonuclease I (10
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body mass index EIN endometrial intraepithelial neoplasia smMIPs single molecule Molecular Inversion Probes units M0293, New England Biolabs, Ipswich, MA) and III (50 units, M0206, New England Biolabs, Ipswich, MA) and Ampligase Buffer were added to the capture volume, adding up to a total of 27 µl, and incubated for 45 min at 37°C followed by inactivation at 95°C for 2 min. A total of 20 µl of the exonuclease treated capture was used for PCR in a total volume of 50 µl with a common forward primer, bar-coded reverse primers, and iProof high fidelity master mix (1725310, Bio-Rad. Veenendaal, the Netherlands). The resulting PCR products were pooled prior to purification with 0.8× volume of Agencourt Ampure XP Beads (A63881, Beckman Coulter, Woerden, The Netherlands).
Sequencing and analysis
Sequencing of libraries diluted to a concentration of 1.2 pM was performed using a NextSeq500 device (Illumina, San Diego, CA) and the 300 cycles Mid Output sequencing kit, resulting in 2 × 150 bp paired-end reads. The Bcl files were converted to fastq files, and bar-coded reads were demultiplexed. Duplicate reads were used to assemble consensus reads using Sequence Pilot software (JSI Medical Systems, Costa Mesa, CA) with the following settings: 
Ethical approval
No ethical approval was needed for this study, which was performed according to the Code for Proper Secondary Use of Human Tissue (Dutch Federation of Biomedical Scientific Societies, www.federa.org).
Results
Cases
DNA isolation, PCR and sequencing were performed for a total of 179 samples, and were successful in 137 (77%), as shown in Table 1 per subgroup. The number of cases with mutations per subgroup, and the number of successfully analyzed genes and mutations per gene are shown in Tables 2 and 3 . Of the 41 pairs of endometrial carcinoma and adjacent endometrium, analysis was unsuccessful for seven complete pairs, eight endometrial carcinomas, and four adjacent endometrium carcinoma samples, leaving 22 pairs to be analyzed. Hyperplastic and atrophic endometrium next to the endometrioid carcinomas, both eleven cases, are shown separately. The endometrium next to the serous carcinomas was heterogeneous, with four cases with pure atrophy, two with pure endometrial hyperplasia and two with a mix of atrophic and hyperplastic endometrium. Due to the small numbers, these cases are not shown separately in the tables. The location and allele frequency of all mutations found are shown in Supplementary 
Mutations in benign and premalignant endometrium
The number of mutated benign and premalignant cases, as well as the genes mutated in these cases, are shown in Table 2 . No mutations were found in the proliferative and atrophic endometrium cases. Of the 62 analyzed cases with endometrial hyperplasia, but no adjacent carcinoma, nine (15%) contained mutations, eight of which contained one mutation and one contained two mutations. A mutation of the EGFR gene was found in one case with simple hyperplasia without atypia. Two PIK3CA mutations were found in the cases with complex hyperplasia without atypia. All other mutations were found in the cases with complex atypical hyperplasia: three KRAS mutations, two PIK3CA mutations and two AKT1 mutations. In comparison, mutations were slightly more common in cases with atypia than in cases without atypia (18 versus 11%), and more common in complex than in simple hyperplasia (30 versus 3%). When comparing the subgroups, cases with complex hyperplasia without atypia and complex atypical hyperplasia were mutated in 22 and 33%, respectively, compared to only one (5%) mutation found in simple hyperplasia without atypia, and none in the cases with simple atypical hyperplasia.
Mutations in carcinomas and adjacent endometrium
The number of mutated carcinoma cases and of the adjacent endometrium, as well as the genes mutated in these cases, are shown in Table 3 . Of the 30 analyzed carcinomas (both endometrioid and non-endometrioid), 14 (43%) contained mutations, 11 of which contained one mutation, and three contained two mutations. Of the 22 included endometrioid carcinomas, 12 cases had a total of 14 mutations, most of which in the KRAS and PIK3CA genes. Five of the six mutations in endometrioid carcinomas next to hyperplastic endometrium were in the KRAS gene and one in the PIK3CA gene. Endometrioid carcinomas next to atrophic endometrium were more heterogeneous: the six cases with mutations contained three PIK3CA mutations, two CTNNB1 mutations, and a KRAS, an AKT1, and an NRAS mutation. One of the three cases with PIK3CA mutations contained two mutations. Two of the cases contained two mutations: one case had a PIK3CA and a CTNNB1 mutation, and the other a PIK3CA and an NRAS. There was only one mutated serous carcinoma, which contained both a PIK3CA and a BRAF mutation.
In the 26 endometrium next to a carcinoma samples, we identified only three (12%) mutations: a KRAS mutation in hyperplastic endometrium next to an endometrioid carcinoma, a PIK3CA mutation in atrophic endometrium next to an endometrioid carcinoma and a KRAS mutation in, interestingly, atrophic endometrium next to a serous carcinoma. Only the KRAS mutation in the hyperplastic endometrium next to an endometrioid carcinoma was identified in the corresponding carcinoma.
Discussion
This study analyzed the presence of mutations in the endometrium, and found no mutations in the included cases with benign endometrium, and only one mutation in the cases with simple hyperplasia. Complex hyperplasia without atypia and complex atypical hyperplasia appear to be important steps in endometrial carcinogenesis, as most mutations were found in these cases. Interestingly, KRAS mutations were very common in endometrioid carcinomas next to hyperplastic endometrium, but not in endometrioid carcinomas next to atrophic endometrium. There were only a few mutations in the endometrium adjacent to the carcinomas.
Mutations
AKT1
Although the PI3K/AKT pathway is frequently affected in endometrial carcinomas, more often than in any other cancer type analyzed by The Cancer Genome Atlas, AKT1 mutations do not seem to play a major role (23, 24) . Shoji et al. (25) analyzed 89 endometrial carcinomas, and found AKT1 mutations in only two cases, both at location c. 49 , and in both cases there were no mutations in the KRAS, PIK3CA and ERBB2 genes. This is comparable to our findings in endometrial carcinomas: we found only one AKT1 mutation, which was at the same position. Interestingly, we found two AKT1 mutations in complex hyperplasia as well, which could imply that these do play a role in endometrial carcinogenesis. However, the allele frequency of these mutations was low, and it is quite possible that they do not play a tumor driving role. This is supported by the fact that we found a much more prevalent KRAS mutation in one of the cases with an AKT1 mutation.
BRAF
Although BRAF is part of the PI3K/AKT pathway as well, it does not seem to play a major role in endometrial carcinomas. There is one publication which analyzed BRAF exons 11 and 15, and found mutations in 21% of the endometrial carcinomas, and in 11% of the complex atypical hyperplasia cases, but not in benign endometrium (26) . However, all of these were novel mutations, and other studies have contested these findings (36, 37) . BRAF mutations do not seem to play a major role in the samples we analyzed, but we did find one previously described BRAF mutation with a high allele frequency in one of the serous carcinomas.
CTNNB1
Previous studies analyzing the CTNNB1 gene in endometrial carcinomas have found CTNNB1 mutations in 15-25% of the endometrioid carcinomas (27, 28) . We found less CTNNB1 mutations than previously described, but it has to be noted that analysis of CTNNB1 was not possible in a substantial number of cases, most likely because FFPE tissue was used for this study. We did not find any CTNNB1 mutations in the other subgroups, but previous studies have only analyzed carcinomas, and we are therefore not able to compare this finding.
EGFR and ERBB2
Immunohistochemical expression of EGFR and Her2/Neu, activated by the PI3K/AKT and MAP/ERK pathways, is frequently seen in endometrial carcinomas, especially in serous carcinomas. EGFR mutations in endometrial carcinomas have not been described, whereas ERBB2 mutations are common in serous carcinomas and uncommon in endometrioid carcinomas (29) (30) (31) (32) . In accordance with these findings, we found only one EGFR mutation in the parts of the gene we sequenced, in a case with simple hyperplasia without atypia. Given the lack of these mutations in complex hyperplasia and endometrial carcinomas, it is unlikely that this gene plays a role in endometrial carcinogenesis. We included only a small number of serous carcinomas, which might explain why we were unable to find any ERBB2 mutations.
KRAS
The presence of KRAS mutations in endometrioid carcinomas has been extensively studied, and these were found in 9-19% (33, 34, 36) . There is one previous study analyzing the presence of KRAS mutation in both endometrioid carcinomas (n = 58) and atypical hyperplasia (n = 22) next to the carcinomas (33) . This study found KRAS mutations in 19% of the carcinoma, and in 5% of the hyperplasia cases. In comparison, we found KRAS mutations in 27% of the endometrioid carcinomas, almost all of which in endometrioid carcinomas next to hyperplastic endometrium. We also found one KRAS mutation in the hyperplasia The absolute number of cases with (specific) mutations relative to the number of cases successfully analyzed are shown between brackets.
a Endometrioid endometrial carcinoma.
next to the carcinoma, and it was present in the adjacent carcinoma as well. In addition, we found KRAS mutations in 5% of the endometrial hyperplasia cases with no adjacent carcinoma, all of which were complex atypical hyperplasia cases.
HRAS and NRAS
Both HRAS and NRAS play a role in the PI3K/AKT pathway as well, and although they have been described in other cancer types which are driven by this pathway, HRAS mutations have never been described in endometrial carcinomas, and NRAS mutations were only found in only 1.8% of the endometrial carcinomas (both endometrioid and non-endometrioid) (28, 34) . This is in line with our findings: we found no HRAS mutations and NRAS mutations in only 5% of the endometrioid carcinomas.
PIK3CA
Oda et al. (35) found PIK3CA mutations in 36% of the 66 endometrial carcinomas studied, and in 26% of the cases PTEN was mutated as well. In addition, Hayes et al. analyzed both these genes in 29 cases with complex atypical hyperplasia and 44 cases with an endometrial carcinoma (12) . They found PTEN mutations in 48% of the complex atypical hyperplasia cases and 57% of the endometrial carcinoma cases. In contrast, they found PIK3CA mutations in only 7% of the complex atypical hyperplasia cases, and in 39% of the endometrial carcinoma cases. They hypothesized that PTEN mutations are a very early event, whereas PIK3CA mutations, amongst others, are important for the invasive potential. This is supported by numerous studies showing either PTEN mutations or loss of immunohistochemical PTEN expression in endometrial hyperplasia (38) (39) (40) .
Premalignancies
Endometrioid carcinomas are assumed to originate from hyperplastic endometrium under the influence of unopposed estrogen expression, and many different mutations have been associated with this process. Especially PTEN mutations are assumed to be an early event, already present in a substantial number of cases with atypical hyperplasia, whereas other mutations, especially of the KRAS and PIK3CA genes, may play a role in the progression from hyperplasia into a carcinoma (12, 24, 35, (38) (39) (40) . Based on several recent studies describing a high risk of up to 30% of progression from atypical hyperplasia into an endometrioid carcinoma, the WHO advises a subdivision of endometrial hyperplasia into non-atypical and atypical hyperplasia (8, 9, 41, 42) . In contrast, the previous subdivision had four categories, and was based on both the architecture (simple or complex) and the absence or presence of atypical nuclei (6) . This was based on a study by Kurman et al., which shows a progression risk of 1% in simple hyperplasia without atypia, 3% in complex hyperplasia without atypia, 8% in simple atypical hyperplasia and 29% in complex atypical hyperplasia (43) . Nevertheless, most recent studies concluding that there is a risk of progression when atypical nuclei are present have pooled simple and complex atypical hyperplasia (8, 41, 42) . However, combining these cases, and subsequently advising a hysterectomy for both diagnoses, is challenged by our findings that almost all mutations are found in complex hyperplasia without atypia and complex atypical hyperplasia, and not in simple atypical hyperplasia. The new WHO subdivision was also based on the fact that many of the mutations present in endometrioid carcinomas were already present in atypical hyperplasia (9) . As previous studies have shown that PTEN mutations are a very early event, followed by other mutations which lead to malignant progression, it might very well be possible that PTEN mutations are already present in simple atypical hyperplasia, but progression mainly occurs as a result of other mutations, which we found predominantly in complex and complex atypical hyperplasia (38) (39) (40) . The traditional morphological characterization has also been challenged by studies suggesting that the identification of endometrioid premalignancies, which were called endometrial intraepithelial neoplasia (EIN), should include assessment of glandular volume, architectural complexity, and nuclear abnormality (44) . Coexistent carcinomas and progression to a carcinoma were found in a substantial number of the EIN cases (45, 46) . Interestingly, EIN was predominantly diagnosed in cases with complex hyperplasia without atypia and complex atypical hyperplasia (45, 46) . Moreover, progression to a carcinoma was most likely to occur if both EIN and complex atypical hyperplasia were present (45, 46) . Little is known about molecular characteristics of EIN, besides the fact that the combined presence of EIN and loss of PTEN predicts the progression risk better than the presence of EIN alone (47) .
All together, these findings suggest that it may be too simplistic to consider all atypical hyperplasia to be the endometrioid premalignancy, and future studies should investigate possible improvements to the histological classification, as well as the combined value of histology and molecular markers in the identification of cases at risk of a coexistent carcinoma or progression to a carcinoma.
Carcinogenesis
It has previously been shown that endometrial hyperplasia can be very focal, and it has been hypothesized that only a few hyperplastic glands are required for endometrial carcinogenesis (48) . This is further supported by the fact that next to around 20% of the endometrioid carcinomas the assumed precursor lesion, endometrial hyperplasia, is not present (16) . Interestingly, in this study we failed to find mutations present in the carcinomas in most of the corresponding endometrial samples, which would support that endometrial carcinogenesis may be a focal process.
Furthermore, previous studies found prognostic and molecular differences between endometrioid carcinomas next to hyperplastic and atrophic endometrium (16, 49) . In the current study, almost all mutations found in the endometrioid carcinomas next to hyperplastic endometrium were in the KRAS gene, whereas endometrioid carcinomas nest to atrophic endometrium were in several other genes other than KRAS. It is of course unknown if these latter carcinomas originated from focal hyperplasic endometrium or directly from atrophic endometrium, but it seems likely that their carcinogenetic pathway is different than that of endometrioid carcinomas next to hyperplastic endometrium. This is further supported by a recent study by Berg et al., which shows that the carcinogenesis of endometrial carcinomas is dependent on the body mass index (BMI), and is characterized by PTEN mutations and PIK3CA mutations in non-obese women, and by KRAS mutations in obese women (50) . Interestingly, a previous study has shown that the BMI of patients with an endometrioid carcinoma with adjacent atrophic endometrium is significantly lower than that of patients with an endometrioid carcinoma with adjacent hyperplastic endometrium (16) . Even when taking into account the fact that we did not include PTEN mutations in our analyses, the fact that we found mutations in only 55% of the endometrioid carcinomas underlines the fact that carcinogenesis of these carcinomas appears to be a very heterogeneous process. Moreover, in light of recent studies classifying endometrial carcinomas based on their molecular profiles, it would be interesting to study the carcinogenesis in relation to this new classification into four subgroups (17, 18) .
The carcinogenesis of non-endometrioid carcinomas is believed to be independent of estrogen stimulation and these carcinomas are assumed to originate directly from atrophic endometrium, although a minority might in fact be dedifferentiated endometrioid carcinomas (2). Interestingly, there was one case which had both a BRAF and a PIK3CA mutation, and was adjacent to hyperplastic endometrium. This might in fact be a dedifferentiated endometrioid carcinoma (2,3).
Strengths and weaknesses
This is the first study analyzing endometrial tissue with smMIPs, which has several advantages over other Next Generation Sequencing techniques (22, 51) . The number of false positive variants with an allele frequency >5% is significantly reduced in the smMIP-NextSeq500 approach, while the detection of clinically relevant mutations is comparable. Additionally, overestimation of the actual number of analyzed molecules as a result of sequence analysis of PCR duplicates is a problem when poor quality FFPE-derived gDNA is used. Because smMIPs have a unique molecular tag the exact number of analyzed input DNA molecules can be calculated, preventing overestimation. Moreover, this is the first study analyzing a substantial number of genes in an extensive and well described, and revised cohort containing benign, premalignant and malignant lesions, as well as endometrium next to the malignant lesions.
Unfortunately, the smMIP analysis was not successful in all cases, most likely as a result of DNA fragmentation caused by the use of FFPE tissue which has been archived for years. In addition, a smMIP probe targeting PTEN was not included in the panel. Although PTEN alterations undeniably play an important role in the development of endometrial carcinomas, this has already been extensively described in other publications highlighting its role in both premalignant and malignant endometrial tissue. The genes described in the current study have been described to play a role in a later stage of carcinogenesis, but there is little data on the presence of these mutations in endometrial tissue other than endometrial carcinomas.
Conclusion
This study reinforces the heterogeneous genetic origin of endometrial carcinogenesis. On a molecular level, complex endometrial hyperplasia appears to be the most important step in this process. Endometrioid carcinogenesis seems to follow different pathways in the presence of hyperplastic and atrophic background endometrium. More research into these distinct carcinogenetic changes and the role of these findings in the management of endometrial carcinomas is needed. Moreover, it should be studied whether non invasive follow-up of patients with simple atypical hyperplasia might be sufficient, possibly with repeated mutation analyses of the endometrial biopsies.
